Search 

Meet MEU at the UK Pavilion (Hall B, Stand 2348).

Medicines Evaluation Unit (MEU) Ltd is one of the UK’s leading CROs, a facility where commitment to excellence is paramount. MEU possess extensive pharmaceutical, scientific and clinical expertise, allied with fast volunteer recruitment, within a state-of-the-art hospital-based research facility.

MEU offer products and services to enable better, safer and more efficient study designs, particularly in complex patient groups. MEU’s bespoke, phenotyped database and trial management system (ICARUS), assists rapid study recruitment ensuring we meet our clients’ timelines. ICARUS possesses over 32,000 active volunteer profiles and enables MEU to assess protocol inclusion criteria, and accurately provide real-time feasibility.

MEU has a team of experienced Principal Investigators led by the world-renowned respiratory KOL Professor Dave Singh, MEU Medical Director. To accelerate drug discovery, MEU have a host of human lung tissue models for target identification and validation studies. The techniques used include cell culture, immunoassays, immunohistochemistry, PCR and flow cytometry.

Meet Micropore Technologies at the UK Pavilion (Hall B, Stand 2348).

Micropore Technologies offers savings in development time, increased yields and simplified operation for those engaged in development and manufacture of parenterals, particularly nano-and micro- sized particles for application in LNPs, PNPs, Polymer microspheres (eg PLGA, PLA), Hydrogels, and many others. We also support our clients with their GMP qualification requirements.

Headquartered in the UK, Micropore has offices in USA and India and has agents in Japan and Australia.

Meet Oribiotech at the UK Pavilion (Hall B, Stand 2348).

Ori is a London and New Jersey based manufacturing technology company pioneering flexible process discovery with seamless translation and scalable commercialization of cell and genetherapies. Ori has developed a proprietary, full stack manufacturing platform that closes, automates and standardizes CGT manufacturing allowing therapeutics developers to develop and bring their products to market at commercial scale. The promise of the innovative Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs by combining proprietary hardware, software, data and analytics. Founded in 2015 by Dr. FarlanVeraitch (UCL), Ori has brought together a seasoned team with over 200 years of combined pharmaceutical, CGT and venture building experience including CEO Jason C. Foster (Indivior), CDOO Kevin Gordon (Tmunity), CTO Stuart Milne (Cytiva), CCO Tom Heathman (Minaris), Chris Mason (AVROBIO), Paul Meister (Thermo Fisher) and Annalisa Jenkins (DimensionTx) alongside expert advisers like Bruce Levine and Robert Preti.

Meet Seda at the UK Pavilion (Hall B, Stand 2348).

Seda Pharmaceutical Development Services provides integrated Pharmaceutical Development and Clinical Pharmacology services to the Biotech sector. We enable rapid and efficient development of optimal medicinal products, from conventional to complex, through pragmatic and coherent scientific excellence. Seda was founded in 2015, and has since demonstrated exceptional growth and expansion in our capabilities which include consultancy, laboratory, and pharmacokinetic modelling services. We provide clients with the experience and expertise found in the development functions of major pharmaceutical companies but with the speed and flexibility required by fast moving Biotechs. Headquartered in Greater Manchester, UK, our bespoke laboratory and office complex is well equipped for the rapid design, development and evaluation of prototype formulation options, from preformulation services, to development of preclinical and clinical formulations. Enhancing the value proposition of our clients is our contribution to bringing new, innovative therapies to patients rapidly and successfully.

Meet Touchlight at the UK Pavilion (Hall B, Stand 2348).

Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.